AI-based Antibody Therapeutics Developability Assessment and Its Engineering

Life Sciences, Drug Discovery & Development, Laboratory Technology,
  • Friday, June 21, 2024 | 10am EDT (NA) / 3pm BST (UK) / 4pm CEST (EU-Central)
  • 60 min

Learn from an informative webinar about how AI-based platforms can facilitate the development process for antibody therapeutics and ensure candidates are not only therapeutically effective but also viable for large-scale production and clinical use.

Monoclonal antibodies (mAbs) have become essential in treating a wide spectrum of diseases, with over 100 therapeutic antibody products now approved and commercially available. Although mAbs represent the fastest-growing sector in therapeutics, their development is complex, with developability being a crucial consideration. Developability evaluates the potential of an antibody candidate to be produced as a safe and effective drug.

In the context of Contract Research and Manufacturing Organizations (CRMOs), the developability assessment focuses on ensuring that an antibody candidate can progress through the chemistry, manufacturing and control (CMC) processes efficiently, affordably and within an acceptable timeframe.


It is important to examine and refine the properties related to developability early on, ideally during the discovery phase, to reduce the chances of advancing an antibody with limited developability to the CMC stage. Artificial intelligence (AI) is transforming bioinformatics research and its applications, particularly in protein and antibody analysis. AI methods are now being employed to improve the developability screening and optimization of antibody candidates.

In this webinar, the expert speaker will present the Immunoinformatics Comprehensive Service Platform, which leverages AI for the developability assessment of antibody therapeutics. This covers assessments of immunogenicity, viscosity, aggregation, degradation and post-translational modifications (PTMs). They will also cover antibody engineering services, including humanization, caninization, felinization and optimizing expression.

Case studies will be presented to demonstrate the capabilities in assessing developability and performing antibody engineering. The webinar will end with a Q&A session, allowing participants to delve into any specific areas of interest regarding AI in antibody development.

Read Less...

Register for this webinar today to learn how AI can be used to improve developability screening of antibody therapeutics and optimization of antibody candidates.


Carter Hao, GenScript

Carter Hao, Senior Bioinformatics Scientist, GenScript

Carter Hao received his PhD in Control Science and Engineering from Zhejiang University of Technology. He is now a Bioinformatics Senior Scientist at GenScript Co. Ltd. and mainly takes charge of the research and development of antibody-related applications. His research interests include protein structure prediction, antibody developability prediction (viscosity, immunogenicity, aggregation and stability), antibody binding affinity maturation, antibody humanization, caninization, felinization and evolution computation. He has published 20+ papers in the above research fields in international journals such as the European Journal of Pharmaceutical SciencesIEEE TCBB and Information Science.

Message Presenter

Who Should Attend?

This webinar will appeal to academic and industry professionals in the following fields:

  • Antibody therapeutics development
  • Antibody discovery and engineering
  • Computational biology and molecular modeling
  • Bioinformatics and immunoinformatics

What You Will Learn

Attendees will learn about:

  • Importance and challenges of developability in antibody therapeutics
  • Role of AI in transforming developability assessment
  • Technological solutions for antibody developability assessment and engineering

Xtalks Partner


GenScript is the leading contract research organization in the world providing gene, peptide, protein, CRISPR, and antibody. Since its foundation in 2002, GenScript has grown exponentially through partnerships with scientists conducting fundamental life science research, translational biomedical research, and early stage pharmaceutical development. The company is recognized as having built a best-in-class capacity and capability for biological research services, encompassing gene synthesis, peptide synthesis, custom antibody and protein engineering, and in vitro and in vivo pharmacology – all with the goal to Make Research Easy.

You Must Login To Register for this Free Webinar

Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.

Create Account